EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Use of Cefiderocol for Multidrug-Resistant Gram-Negative Infections in Critically Ill ICU Patients: A Single-Center Case Series

Real-World-Anwendung von Cefiderocol bei multiresistenten gramnegativen Infektionen bei kritisch kranken ICU-Patient:innen: eine Fallserie aus einem Zentrum

Stelian Adrian Ritiu iD, Adelina Baloi, Marius Păpurică iD, Dorel Sandesc, Daiana Toma iD, Claudiu Rafael Bârsac iD, Sonia Elena Popovici iD, Madalina Butaș, Ana-Maria-Ionela Botoaca, Ovidiu Bedreag iD

Pathogens · 24.07.2026 · 15 (8) · 786

DOI: 10.3390/pathogens15080786 ↗

Auf einen Blick

In einer Fallserie mit 25 kritisch kranken ICU-Patient:innen war Cefiderocol mit mikrobiologischer Eradikation bei 68 % verbunden. Eine frühere Gabe war mit günstigeren mikrobiologischen und klinischen Verläufen assoziiert.

Fragestellung

Welche mikrobiologischen und klinischen Ergebnisse waren bei kritisch kranken Patient:innen mit MDR-gramnegativen Infektionen unter Cefiderocol zu beobachten?

Methode

Retrospektive Fallserie aus einem Zentrum; 25 kritisch kranke Patient:innen mit carbapenemresistenten oder MDR-gramnegativen Infektionen; Behandlung mit Cefiderocol zwischen Mai 2024 und Oktober 2025 auf einer gemischten ICU in Rumänien.

Ergebnisse

K. pneumoniae war bei 23/25 Patient:innen (92 %) der häufigste Erreger, A. baumannii bei 11/25 (44 %) und P. aeruginosa bei 6/25 (24 %). Mikrobiologische Heilung: 68 %. Mortalität höher ohne Eradikation (88 % vs. 35 %).

Einschränkungen

Retrospektiv, single-center, ohne Vergleichsgruppe; Kausalität nicht ableitbar.

Schlussfolgerung der Autor:innen

Cefiderocol war mit klinisch relevanten mikrobiologischen Eradikationsraten und Verbesserungen klinischer Parameter assoziiert. Die Ergebnisse sprechen für eine mögliche Salvage-Option, müssen aber prospektiv bestätigt werden.

Kernaussagen

  • Mikrobiologische Heilung bei 68 % der Patient:innen
  • Ohne Eradikation höhere Mortalität: 88 % vs. 35 %
  • Frühere Cefiderocol-Gabe mit günstigeren Outcomes assoziiert

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, online erschienen am 24.07.2026. Verfasst von Stelian Adrian Ritiu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania. Hauptthemen laut MEDLINE: Cephalosporins, Gram-Negative Bacterial Infections, Drug Resistance, Multiple, Bacterial, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Victor Babes University of Medicine and Pharmacy, Sobi Romania.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Carbapenem-resistant Gram-negative (CR-GN) infections are associated with high mortality in intensive care units (ICUs), with limited therapeutic options. We aimed to evaluate microbiological and clinical outcomes associated with cefiderocol in critically ill patients with multidrug-resistant (MDR) Gram-negative infections.

Methods

This retrospective, single-center case series included 25 critically ill patients with carbapenem-resistant or multidrug-resistant Gram-negative infections treated with cefiderocol between May 2024 and October 2025 in a mixed ICU of a tertiary hospital in Romania. Microbiological cure was defined as eradication of the designated target pathogen at the end of therapy. Clinical evolution was assessed using the Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores, as well as inflammatory biomarkers including white blood cell count (WBC), C-reactive protein (CRP), and procalcitonin (PCT).

Results

Klebsiella pneumoniae was the predominant pathogen, identified in 23 of 25 patients (92%), followed by Acinetobacter baumannii (11/25, 44%) and Pseudomonas aeruginosa (6/25, 24%). As multiple pathogens were co-isolated in 16 patients (64%), percentages exceed 100% and are reported as proportions of patients rather than of total isolates. Microbiological cure was achieved in 68% of patients. Mortality was markedly higher in patients without microbiological eradication (88% vs. 35%). Higher baseline APACHE II (HR 1.18, 95% CI 1.02–1.37) and SOFA scores (HR 1.33, 95% CI 1.07–1.65) were associated with increased mortality. Early initiation of cefiderocol (≤10 days from ICU admission) was associated with improved microbiological and clinical outcomes compared to delayed treatment. Reductions in severity scores and inflammatory markers, including C-reactive protein (CRP) and procalcitonin (PCT), were observed during therapy. Pathogen type and combination therapy were not clearly associated with outcomes in this cohort.

Conclusions

Cefiderocol was observed in association with clinically relevant rates of microbiological eradication and improvements in clinical parameters in critically ill patients with MDR Gram-negative infections. Outcomes appeared to be primarily determined by baseline disease severity, while earlier initiation of therapy was associated with more favourable microbiological and clinical outcomes, although causality cannot be established given the observational design and absence of a comparator group. These findings are hypothesis-generating and supportive of a potential role for cefiderocol as a salvage option in high-risk ICU populations, pending validation in larger, prospective, controlled studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CephalosporinsGram-Negative Bacterial InfectionsDrug Resistance, Multiple, BacterialAnti-Bacterial AgentsGram-Negative BacteriaHumansCefiderocolFemaleCritical IllnessIntensive Care UnitsRetrospective StudiesMaleMiddle AgedAgedTreatment Outcome

Stichwörter der Autor:innen

ICUcarbapenem resistancecefiderocolcritically ill patientslimited option antibiotic therapymicrobiological eradicationpolymicrobial infection

Substanzen

CefiderocolCephalosporinsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Faculty of Medicine, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania.
  • Clinic of Anaesthesia and Intensive Care, Emergency County Hospital Pius Brinzeu, 300723 Timisoara, Romania.
  • Doctoral School, Victor Babes University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
  • Anaesthesia and Intensive Care Research Center (CCATITM), Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania.

ORCID-Profile: Stelian Adrian Ritiu, Marius Păpurică, Daiana Toma, Claudiu Rafael Bârsac, Sonia Elena Popovici, Ovidiu Bedreag

Förderung

  • Victor Babes University of Medicine and Pharmacy
  • Sobi Romania

Zitieren

APA

Ritiu, S. A., Baloi, A., Păpurică, M., Sandesc, D., Toma, D., Bârsac, C. R., Popovici, S. E., Butaș, M., Botoaca, A. M., & Bedreag, O. (2026). Real-World Use of Cefiderocol for Multidrug-Resistant Gram-Negative Infections in Critically Ill ICU Patients: A Single-Center Case Series. Pathogens, 15(8), 786. https://doi.org/10.3390/pathogens15080786

Vancouver

Ritiu SA, Baloi A, Păpurică M, Sandesc D, Toma D, Bârsac CR, et al. Real-World Use of Cefiderocol for Multidrug-Resistant Gram-Negative Infections in Critically Ill ICU Patients: A Single-Center Case Series. Pathogens. 2026;15(8):786. doi:10.3390/pathogens15080786

BibTeX
@article{Ritiu2026,
  author = {Ritiu, Stelian Adrian and Baloi, Adelina and Păpurică, Marius and Sandesc, Dorel and Toma, Daiana and Bârsac, Claudiu Rafael and Popovici, Sonia Elena and Butaș, Madalina and Botoaca, Ana-Maria-Ionela and Bedreag, Ovidiu},
  title = {Real-World Use of Cefiderocol for Multidrug-Resistant Gram-Negative Infections in Critically Ill ICU Patients: A Single-Center Case Series},
  journal = {Pathogens},
  year = {2026},
  volume = {15},
  number = {8},
  pages = {786},
  doi = {10.3390/pathogens15080786}
}
Kostenlos starten →